AR125232A2 - HUMAN MONOCLONAL ANTIBODIES NEUTRALIZING TO TETANUS TOXIN AGAINST AN INFECTION BY C. TETANI, METHOD FOR OBTAINING SUCH MONOCLONAL ANTIBODIES AND THEIR USE IN IMMUNOTHERAPIES FOR ACCIDENTS SUSCEPTIBLE TO AN INFECTION BY TETANUS BACILLUS - Google Patents

HUMAN MONOCLONAL ANTIBODIES NEUTRALIZING TO TETANUS TOXIN AGAINST AN INFECTION BY C. TETANI, METHOD FOR OBTAINING SUCH MONOCLONAL ANTIBODIES AND THEIR USE IN IMMUNOTHERAPIES FOR ACCIDENTS SUSCEPTIBLE TO AN INFECTION BY TETANUS BACILLUS

Info

Publication number
AR125232A2
AR125232A2 ARP220100737A ARP220100737A AR125232A2 AR 125232 A2 AR125232 A2 AR 125232A2 AR P220100737 A ARP220100737 A AR P220100737A AR P220100737 A ARP220100737 A AR P220100737A AR 125232 A2 AR125232 A2 AR 125232A2
Authority
AR
Argentina
Prior art keywords
tetanus
infection
monoclonal antibodies
immunotherapies
tetani
Prior art date
Application number
ARP220100737A
Other languages
Spanish (es)
Inventor
Eduardo Aliprandini
Filho Jorge Elias Kalil
Ana Maria Moro
Original Assignee
Fund Butantan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fund Butantan filed Critical Fund Butantan
Publication of AR125232A2 publication Critical patent/AR125232A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Anticuerpos monoclonales humanos anti-toxina de tétano contra una infección por C. tetani, que se obtienen mediante técnicas de ingeniería genética utilizando como base la información de secuencias genéticas obtenida a partir de linfocitos B de sangre periférica de individuos inmunizados con el toxoide del tétano. La información genética se inserta en vectores que se utilizarán para transfectar células de mamífero con el objeto de generar linajes celulares productores de los anticuerpos monoclonales anti-toxina de tétano. En otro aspecto, la presente invención se refiere a composiciones inmunológicas que contienen dicho anticuerpo monoclonal, así como a sus usos en el tratamiento y/o en inmunoterapias de una infección por tétano. Reivindicación 1: Un anticuerpo monoclonal anti-tétano humano, caracterizado porque dicho anticuerpo es un anticuerpo monoclonal 2-BUT-TT-143 que comprende una región variable de la cadena pesada VH que comprende una secuencia de aminoácidos que está representada por la SEQ ID Nº 8 y una región variable de la cadena liviana VL que comprende una secuencia de aminoácidos que está representada en la SEQ ID Nº 6.Human anti-tetanus toxin monoclonal antibodies against a C. tetani infection, which are obtained by genetic engineering techniques using as a basis genetic sequence information obtained from peripheral blood B lymphocytes of individuals immunized with tetanus toxoid. The genetic information is inserted into vectors that will be used to transfect mammalian cells in order to generate cell lines that produce anti-tetanus toxin monoclonal antibodies. In another aspect, the present invention relates to immunological compositions containing said monoclonal antibody, as well as their uses in the treatment and/or in immunotherapies of a tetanus infection. Claim 1: A human anti-tetanus monoclonal antibody, characterized in that said antibody is a 2-BUT-TT-143 monoclonal antibody that comprises a variable region of the VH heavy chain that comprises an amino acid sequence that is represented by SEQ ID No. 8 and a VL light chain variable region comprising an amino acid sequence that is represented in SEQ ID NO: 6.

ARP220100737A 2016-07-29 2022-03-28 HUMAN MONOCLONAL ANTIBODIES NEUTRALIZING TO TETANUS TOXIN AGAINST AN INFECTION BY C. TETANI, METHOD FOR OBTAINING SUCH MONOCLONAL ANTIBODIES AND THEIR USE IN IMMUNOTHERAPIES FOR ACCIDENTS SUSCEPTIBLE TO AN INFECTION BY TETANUS BACILLUS AR125232A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102016017782-0A BR102016017782A2 (en) 2016-07-29 2016-07-29 NUTRIENTING ANTITETANIC HUMAN MONOCLONAL ANTIBODIES FOR C.TETANI INFECTION, METHOD FOR OBTAINING MONOCLONAL ANTIBODIES AND THEIR USE IN IMMUNOTHERAPY FOR TETANIC BACILE INFECTION

Publications (1)

Publication Number Publication Date
AR125232A2 true AR125232A2 (en) 2023-06-28

Family

ID=59955306

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP170102180A AR109221A1 (en) 2016-07-29 2017-07-31 HUMAN ANTITETHANE MONOCLONAL ANTIBODIES THAT NEUTRALIZE AN INFECTION BY C. TETANI, METHOD FOR OBTAINING THE MONOCLONAL ANTIBODIES AND THEIR USE IN IMMUNOTHERAPIES OF ACCIDENTAL INJURIES SUSCEPTIBLE TO AN INFECTION BY A BATH TANK
ARP220100736A AR125231A2 (en) 2016-07-29 2022-03-28 HUMAN MONOCLONAL ANTIBODIES NEUTRALIZING TO TETANUS TOXIN AGAINST AN INFECTION BY C. TETANI, METHOD FOR OBTAINING SUCH MONOCLONAL ANTIBODIES AND THEIR USE IN IMMUNOTHERAPIES FOR ACCIDENTS SUSCEPTIBLE TO AN INFECTION BY TETANUS BACILLUS
ARP220100737A AR125232A2 (en) 2016-07-29 2022-03-28 HUMAN MONOCLONAL ANTIBODIES NEUTRALIZING TO TETANUS TOXIN AGAINST AN INFECTION BY C. TETANI, METHOD FOR OBTAINING SUCH MONOCLONAL ANTIBODIES AND THEIR USE IN IMMUNOTHERAPIES FOR ACCIDENTS SUSCEPTIBLE TO AN INFECTION BY TETANUS BACILLUS

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP170102180A AR109221A1 (en) 2016-07-29 2017-07-31 HUMAN ANTITETHANE MONOCLONAL ANTIBODIES THAT NEUTRALIZE AN INFECTION BY C. TETANI, METHOD FOR OBTAINING THE MONOCLONAL ANTIBODIES AND THEIR USE IN IMMUNOTHERAPIES OF ACCIDENTAL INJURIES SUSCEPTIBLE TO AN INFECTION BY A BATH TANK
ARP220100736A AR125231A2 (en) 2016-07-29 2022-03-28 HUMAN MONOCLONAL ANTIBODIES NEUTRALIZING TO TETANUS TOXIN AGAINST AN INFECTION BY C. TETANI, METHOD FOR OBTAINING SUCH MONOCLONAL ANTIBODIES AND THEIR USE IN IMMUNOTHERAPIES FOR ACCIDENTS SUSCEPTIBLE TO AN INFECTION BY TETANUS BACILLUS

Country Status (4)

Country Link
AR (3) AR109221A1 (en)
BR (1) BR102016017782A2 (en)
PH (1) PH12019500431A1 (en)
WO (1) WO2018018123A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110845609B (en) * 2019-11-26 2021-06-15 武汉生物制品研究所有限责任公司 Detection antibody pair aiming at tetanus toxoid and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2627076B2 (en) 1988-08-19 1997-07-02 森永製菓株式会社 Anti-tetanus toxin human monoclonal antibody, neutralizing agent for tetanus toxin using the same, and hybridoma producing human monoclonal antibody
DE69225791T2 (en) 1992-03-23 1998-10-22 Schweiz Serum & Impfinst Monoclonal antibodies to tetanus toxin and pharmaceutical compositions containing them
JPH1014570A (en) 1996-07-05 1998-01-20 Morihiro Matsuda Antibody dna
CN102453091B (en) 2010-10-20 2013-09-25 上海生物制品研究所有限责任公司 Tetanus toxoid monoclonal antibody and preparation method and application thereof
CN105153305B (en) 2015-06-26 2019-03-01 安泰吉（北京）生物技术有限公司 A kind of full humanized anti-spasmotoxin monoclone antibody and its derivative preparation method and application

Also Published As

Publication number Publication date
WO2018018123A2 (en) 2018-02-01
BR102016017782A2 (en) 2018-02-14
AR109221A1 (en) 2018-11-07
WO2018018123A3 (en) 2018-03-22
PH12019500431A1 (en) 2019-10-28
AR125231A2 (en) 2023-06-28

Similar Documents

Publication Publication Date Title
MY189819A (en) Genetically modified cells and uses thereof
BR112017019140A2 (en) cancer treatment methods using activated t cells
SA520411173B1 (en) Binding Agents Binding to PD-L1 and CD137 and Use Thereof
BR112021016178A2 (en) Universal donor stem cells and related methods
AR071510A1 (en) ANTI-FACTOR D HUMANIZED ANTIBODIES AND THEIR USES
BR112018008442A2 (en) chimeric receptors containing traf inducer domains and related compositions and methods
CO2022017670A2 (en) Antibodies against sars-cov-2
AR110645A1 (en) ANTI-HLA-G ANTIBODIES AND USE OF THE SAME
PE20210517A1 (en) ANTI-HLA-G ANTIBODIES AND THE USE OF THEM
GT201100023A (en) NEUTRALIZING ANTIBODIES OF VIRUS ANTI - INFLUENZA A AND USES OF THE SAME
ZA202206809B (en) Hiv vaccines comprising one or more population episensus antigens
BR112018067946A8 (en) TOPICAL FORMULATIONS CONTAINING CYCLOSPORINE AND USES THEREOF
AR090668A1 (en) ANTI-ADAMTS-5 ANTIBODY, DERIVATIVES AND USES OF THE SAME
EA202091349A1 (en) METHODS OF CELL CULTIVATION
EA201790558A1 (en) COMPOSITION WITH REDUCED IMMUNOGENICITY
MX2018014554A (en) Cytosol-penetrating antibody and use thereof.
AR125232A2 (en) HUMAN MONOCLONAL ANTIBODIES NEUTRALIZING TO TETANUS TOXIN AGAINST AN INFECTION BY C. TETANI, METHOD FOR OBTAINING SUCH MONOCLONAL ANTIBODIES AND THEIR USE IN IMMUNOTHERAPIES FOR ACCIDENTS SUSCEPTIBLE TO AN INFECTION BY TETANUS BACILLUS
CY1123467T1 (en) THERAPEUTIC VACCINE FOR THE TREATMENT OF CHILDREN'S TYPE 1 DIABETES, APPLICATION OF FLOW CYTOMETRY CELL SEPARATION AND TREG CELL PROPAGATION METHOD FOR THE PRODUCTION OF THERAPEUTIC VACCINE FOR THE TREATMENT OF DIABETES T UNDER 1
BR112023018844A2 (en) COMPOSITIONS AND METHODS FOR GENERATION OF GAMMA-DELTA T CELLS FROM INDUCED PLURIPOTENT STEM CELLS
EP4316497A3 (en) Mesenchymal stem cells as vaccine adjuvants and methods for using the same
BR112016018826A8 (en) purified antibody, or antigen binding fragment, method for identifying a population of mammalian sperm cells carrying the x chromosome, and in vitro method for distorting a sex ratio
BR112022022514A2 (en) ARTIFICIAL ANTIGEN-PRESENTING CELL SYSTEM AND USES THEREOF
EA201992828A1 (en) METHODS OF CULTIVATION OF CELLS
CL2023001816A1 (en) Modified parapoxvirus having increased immunogenicity
PE20191767A1 (en) COMPOSITIONS AND METHODS FOR THE INCREASED PRODUCTION OF ENDURACIN IN A GENETICALLY MODIFIED STREPTOMYCES FUNGICIDICUS STRAIN